Plain-English translation of NCT06680232 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is a Phase 1 trial testing a new treatment called for people with chronic hepatitis B. Researchers want to see if this medication is safe, how the body handles it, and whether it can help reduce the hepatitis B virus. The study starts with small doses and carefully increases them to find the safest and most effective level.
Even though current antiviral medications can control hepatitis B, many people must take them indefinitely and the virus can persist. This trial explores whether this new treatment could offer a different approach to potentially achieve better long-term control of the infection.
You likely qualify if…
You likely don't qualify if…
You will receive multiple intravenous infusions of the medication over time as part of a finite course of treatment. The study has two parts: in the first part, doctors carefully test increasing doses to find a safe level, and in the second part, additional participants receive the dose that worked best. Throughout the trial, you'll have regular visits for blood work, health checks, and monitoring of how the treatment affects your hepatitis B virus levels.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
United States
France
Hong Kong
Moldova
New Zealand